Press Releases<< Back
CHF Solutions Announces COVID-19 Patients Treated with Aquadex Therapy for Fluid Management
In the last week, critically ill patients in
The World Health Organization (WHO) recently released a protocol for treating patients infected with COVID-19, highlighting the need for effective fluid management treatment strategies when caring for the critical patient population because the risk of volume overload is very high.1
In a physician webinar hosted last week, three panelists: Dr. Amir Kazory, M.D., FASN (
“We are pleased that we can help critical care patients during this time of need,” said
“We want to take this opportunity to thank and extend our most sincere gratitude to the first responders, medical teams taking care of the critically ill patients, and all the people and organizations working to contain COVID-19,” said
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the clinical use of the Aquadex SmartFlow system in patients infected with COVID-19. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
1 WHO reference number: WHO/nCoV/Clinical/2020.3
Claudia Napal DraytonChief Financial Officer, CHF Solutions, Inc.952-345-4205 firstname.lastname@example.org MEDIA: Brad PerrielloHealth+Commerce 617-817-1385 email@example.com
Source: CHF Solutions, Inc.